Lantern Pharma Inc’s $26.25M Initial Public Offering Common Stock

Blank Rome advised Think Equity as representative of the underwriters.

Lantern Pharma closed the pricing of its initial public offering of 1,750,000 shares of its common stock at a public offering price of $15.00 per share, for gross proceeds of $26,250,000, before deducting underwriting discounts, commissions and offering expenses.

In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 262,500 shares of common stock at the initial public offering price, less the underwriting discount, to cover over-allotments.

ThinkEquity, a division of Fordham Financial Management, Inc. acted as sole book-running manager for the offering. Colliers Securities LLC and Paulson Investment Company, LLC acted as co-managers for the offering.

Lantern Pharma Inc. (LTRN) is a clinical stage biotechnology company, focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from our targeted oncology therapies.

Blank Rome team included Brad L. Shiffman (Picture), Elena P. Jacque, Emanuel J. Adler, Andrae A. D. Nelson.

Involved fees earner: Emanuel Adler – Blank Rome LLP; Elena Jacque – Blank Rome LLP; Andrae Nelson – Blank Rome LLP; Brad Shiffman – Blank Rome LLP;

Law Firms: Blank Rome LLP;

Clients: Think Equity ;

Author: Ambrogio Visconti